US Pharma MarketingThe post Veradermics’ stock up on male hair loss trial success appeared first on Clinical Trials Arena.
Veradermics’ stock up on male hair loss trial success
Veradermics said that its drug could be the first approved by the FDA for male hair loss in almost three decades. The company said that its drug could be the first approved by the FDA for this patient population in almost three decades. The drug has now met its endpoints in two Phase III trials. Credit: maxbelchenko / Shutterstock.com Veradermics’ stock was up nearly 6% at market open today after a Phase III trial evaluating its hair loss drug met all endpoints. In Study ‘304’ (NCT06972264), patients treated with VDPHL01 achieved superior hair growth compared with placebo on the co‑primary…
Veradermics said that its drug could be the first approved by the FDA for male hair loss in almost three decades.
Source: Clinical Trials Arena